An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 6, 2008, Pages 1270-1273

  Matzno, Sumio ^a   Yamaguchi, Yuka ^a   Akiyoshi, Takeshi ^a   Nakabayashi, Toshikatsu ^a   Matsuyama, Kenji ^b  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Etoposide; G2 M arrest; Hepatic cancer; Vitamin K3

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; ESTERASE; ETOPOSIDE; IRINOTECAN; MENADIONE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL STRAIN HEPG2; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; FLOW CYTOMETRY; G2 PHASE; HUMANS; INDICATORS AND REAGENTS; LIVER NEOPLASMS; VITAMIN K 3;

EID: 45749097057     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1270     Document Type: Article

References (27)

1. Cranenburg E. C., Schurgers L. J., Vermeer C., Thromb. Haemost., 98, 120-125 (2007).
2. Falanga A., Pathophysiol. Haemost. Thromb., 33, 389-392 (2003).
3. Lamson D. W., Plaza S. M., Altern. Med. Rev., 8, 303-318 (2003).
4. Falanga A., Marchetti M., Vignoli A., Balducci D., Clin. Adv. Hematol. Oncol., 1, 673-678 (2003).
5. Piccioli A., Falanga A., Prandoni P., Semin. Thromb. Hemost., 32, 810-813 (2006).
6. Juan C. C., Wu F. Y., Biochem. Biophys. Res. Commun., 190, 907-913 (1993).
7. Nishikawa Y., Carr B. I., Wang M., Kar S., Finn F., Dowd P., Zheng Z. B., Kerns J., Naganathan S., J. Biol. Chem., 270, 28304-28310 (1995).
8. Gant T. W., Rao D. N., Mason R. P., Cohen G. M., Chem. Biol. Interact., 65, 157-173 (1988).
9. Sun J. S., Tsuang Y. H., Huang W. C., Chen L. T., Hang Y. S., Lu F. J., Cell Mol. Life. Sci., 53, 967-976 (1997).
10. Sata N., Klonowski-Stumpe H., Han B., Haussinger D., Niederau C., Free Radic. Biol. Med., 23, 844-850 (1997).
11. Markovits J., Wang Z., Carr B. I., Sun T. P., Mintz P., Le Bret M., Wu C. W., Wu F. Y., Life Sci., 72, 2769-2784 (2003).
12. Tamura K., Southwick E. C., Kerns J., Rosi K., Carr B. I., Wilcox C., Lazo J. S., Cancer Res., 60, 1317-1325 (2000).
13. Wang Z., Southwick E. C., Wang M., Kar S., Rosi K. S., Wilcox C. S., Lazo J. S., Carr B. I., Cancer Res., 61, 7211-7216 (2001).
14. Carr B. I., Wang Z., Wang M., Kar S., Wilcox C. S., Rosi K., Southwick E., Lazo J. S., J. Mol. Biol., 326, 721-735 (2003).
15. Sakamoto S., Yokoyama M., Zhang X., Prakash K., Nagao K., Hatanaka T., Getzenberg R. H., Kakehi Y., Endocrinology, 145, 2929-2940 (2004).
16. Desai D., Wessling H. C., Fisher R. P., Morgan D. O., Mol. Cell. Biol., 15, 345-350 (1995).
17. Morgan D. O., Nature (London), 374, 131-134 (1995).
18. Smits V. A., Medema R. H., Biochim. Biophys. Acta, 1519, 1-12 (2001).
19. Hsiang Y. H., Liu L. F., Cancer Res., 48, 1722-1726 (1988).
20. Mathijssen R. H., Loos W. J., Verweij J., Sparreboom A., Curr. Cancer Drug Targets, 2, 103-123 (2002).
21. Ray S., Shyam S., Fraizer G. C., Almasan A., Mol. Cancer Ther., 6, 1368-1378 (2007).
22. Hande K. R., Eur. J. Cancer, 34, 1514-1521 (1998).
23. Hande K. R., Biochim. Biophys. Acta, 1400, 173-184 (1998).
24. Nam C., Yamauchi H., Nakayama H., Doi K., Neurotoxicol. Teratol., 28, 664-672 (2006).
25. Berenbaum M. C., Clin. Exp. Immunol., 28, 1-18 (1977).
26. Steel G. G., Int. J. Radiat. Oncol. Biol. Phys., 5, 1145-1150 (1979).
27. Kano Y., Akutsu M., Tsunoda S., Mori K., Suzuki K., Adachi K. I., Cancer Chemother. Pharmacol., 42, 91-98 (1998).